Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 455 results for "Ibrutinib"

BRIEF-Janssen to present data from 6 compounds at 2016 ASCO an...

May 18 Janssen Research & Development LLC: * Janssen to present data from six compounds including Daratumumab and Ibrutinib at the 2016 American Society of Clinical Oncology (ASCO) annual meeting Source text for Eikon: Further company coverage: ... Reuters UK, 1 week ago
[x]  

6 images for Ibrutinib

Pharmafile, 2 weeks ago
Cancer Therapy Advisor, 1 month ago
OncLive, 1 month ago
Irish Medical Times, 1 month ago
OncoTherapy Network, 1 month ago
MDLinx, 1 month ago
Pharmafile

U.S. FDA Expands IMBRUVICA ibrutinib Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia CLL and New...

U.S. FDA Expands IMBRUVICA ibrutinib Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia CLL and New Indication for Small Lymphocytic Lymphoma SLL Patients By a News Reporter-Staff News Editor at Biotech ...
 Pharmacy Choice4 days ago Growth Kinetics May Help Identify Ibrutinib Resistance in CLL Patients  OncoTherapy Network4 days ago FDA Updates Ibrutinib Labeling to Include Survival Data  ASH Clinical News1 week ago Extended RESONATE Data Illuminates Ibrutinib's Benefits in High-Risk CLL  Targeted Oncology1 week ago
[x]  

Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) for Expanded Use in Chronic Lymph

Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a Positive Opinion, recommending broadening the existing marketing authorisation for ibrutinib ...
 Global Hospital & Healthcare Management2 weeks ago European CHMP Recommends Approval for Front-line Use of Ibrutinib for CLL  ASH Clinical News2 weeks ago Janssen/AbbVie's Imbruvica boosted by US label update  pharmaphorum2 weeks ago Ibrutinib receives positive CHMP opinion for expanded use in previously untreated CLL patients  Ecancer Medicalscience3 weeks ago
[x]  

Health Canada approves IMBRUVICA® (ibrutinib) as a treatment for Waldenström's Macroglobulinemia

TORONTO, ON Janssen Inc. reports that Health Canada has issued a Notice of Compliance (NOC) for IMBRUVICA® (ibrutinib), for the treatment of patients with Waldenström's macroglobulinemia (WM). WM is a rare, incurable type of non-Hodgkin ...
 BiotechnologyFocus.ca1 week ago Health Canada Approves IMBRUVICA (ibrutinib) for the Treatment of Waldenström's Macroglobulinemia  FirstWord Pharma2 weeks ago Ibrutinib and Waldenstroms Macroglobulin...  Oncology Tube1 month ago How to decide between Ibrutinib and Idel...  Oncology Tube1 month ago
[x]  

Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology

-Studies demonstrate potential mechanistic synergies with the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, as well as with immunomodulation- BOSTON--(EON: Enhanced Online News Overall these data further support the broad versatility and ...
 EON: Enhanced Online News1 month ago Acetylon Pharmaceuticals Announces The Presentation Of Preclinical Data At AACR Supporting The Use Of Selective HDAC6 Inhibition To Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology  BioSpace1 month ago
[x]  

Venetoclax achieves responses in CLL refractory to ibrutinib, idelalisib

0 Flares 0 Flares × FROM ASCO 2016 Venetoclax monotherapy was active, and even elicited minimal residual disease negativity in a proportion of patients with chronic lymphocytic leukemia (CLL) that was resistant or refractory to ibrutinib or ...
 PM 3602 days ago

Abstract: Ibrutinib with Low-Dose Dexame...

Abstract: Ibrutinib with Low-Dose Dexamethasone in Relapsed or Relapsed and Refractory
 Oncology Tube4 days ago

Debate: Optimal approach for the management of CLL patients with del(17p) - Ibrutinib

A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/A... A continuing education program is offered as a supplement to this webcast at the following location: ...
 Oncology Tube6 days ago

Abstract: Single-agent Ibrutinib 420mg Induces Durable Responses in Patients with CLL

imedex has 822 videos Subscribe Here Loading........ Video URL : Embed : Description: In this abstract presentation, Dr. Steve Coutre discusses the use of 420 mg of single-agent ibrutinib to induce durable responses including complete ...
 Oncology Tube1 week ago
Cancer Therapy Advisor

ASCO 2015: New Ibrutinib Combination Reg...

Description: An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients with chronic-lymphocytic leukemia (CLL) that worsened despite prior therapy. At a ...
 Oncology Tube1 week ago Ibrutinib Plus Bendamustine and Rituximab Yields Positive Results for Patients With CLL/SLL  ASH Clinical News1 month ago Bendamustine + Rituximab Effective for Untreated CLL in 'Real-life' Study  Cancer Therapy Advisor3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Ibrutinib
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less